Emily Szabo
Emily Szabo has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Allison Hess-Dunning
Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, 44106, USA; Advanced Platform Technology Center, Louis Stokes Cleveland Veterans Affairs Medical Center, Cleveland, OH, 44106, USA
1 shared publication - Amber U. Luong
The University of Texas Health Science Center at Houston
1 shared publication - Amelia Howe
Neuronoff, Inc., Cleveland, OH 44106, USA
1 shared publication - Anthony G. Del Signore
Otolaryngology Mount Sinai Beth Israel New York New York USA
1 shared publication - Clare Marie Rimnac
Senior Editor, Clinical Orthopaedics and Related Research®, Schaumburg, IL, USA
1 shared publication Clare Rimnac
Case Western Reserve University, Department of Mechanical and Aerospace Engineering, 2123 Martin Luther King Jr Dr, Cleveland, OH 44106, USA
1 shared publication
Latest Publications
- Open Access
- 7 October 2026
- Published by Wiley in Otolaryngology–Head and Neck Surgery
Cryotherapy as Treatment for Chronic Rhinitis: Long‐Term Results of a Prospective, Multicenter Registry
Objective: The purpose of this registry was to capture observational data on a large and diverse cohort treated with the ClariFix Cryotherapy device for chronic rhinitis. Study Design: Prospective, multicenter, nonrandomized, observational registry. Setting: Twenty‐two tertiary care and private otolaryngology practices. Methods: ClariFix treatment was administered to adult patients with allergic or nonallergic chronic rhinitis. Outcome measures included the reflective Total Nasal Symptom Score, mini Rhinoconjunctivitis Quality of Life Questionnaire, Patient Global Impression of Change, Clinician Global Impression‐Improvement, and adverse events related to the device or procedure through 24‐month follow‐up. Results: A total of 354 participants received 932 treatments. The mean change in total reflective Total Nasal Symptom Score from baseline to all follow‐ups was significant ( P < .001); greater than 73% of participants were responders, achieving ≥1 point reduction at all follow‐ups. Participants with baseline reflective Total Nasal Symptom scores ≥ 7 had greater improvement than those with baseline scores < 7 ( P < .001). Greater than 74% of participants were quality of life responders (≥0.4 points) at all follow‐ups with the mini Rhinoconjunctivitis Quality of Life Questionnaire. More than 73% of participants reported PGIC improvement at all follow‐ups. Clinicians noted improvement in 87.1% of participants at 3‐month follow‐up. No device‐ or treatment‐related serious adverse events were reported. Device‐ and treatment‐related adverse events were transient, nonserious, and typically resolved by over‐the‐counter medication and warm beverages. Conclusion: This registry provides additional long‐term evidence of the safety and efficacy of cryotherapy for the treatment of chronic rhinitis in a diverse population through 24 months.
- 7 October 2026
- Published by Wiley in Otolaryngology–Head and Neck Surgery
Open AccessCryotherapy as Treatment for Chronic Rhinitis: Long‐Term Results of a Prospective, Multicenter Registry
Objective: The purpose of this registry was to capture observational data on a large and diverse cohort treated with the ClariFix Cryotherapy device for chronic rhinitis. Study Design: Prospective, multicenter, nonrandomized, observational registry. Setting: Twenty‐two tertiary care and private otolaryngology practices. Methods: ClariFix treatment was administered to adult patients with allergic or nonallergic chronic rhinitis. Outcome measures included the reflective Total Nasal Symptom Score, mini Rhinoconjunctivitis Quality of Life Questionnaire, Patient Global Impression of Change, Clinician Global Impression‐Improvement, and adverse events related to the device or procedure through 24‐month follow‐up. Results: A total of 354 participants received 932 treatments. The mean change in total reflective Total Nasal Symptom Score from baseline to all follow‐ups was significant ( P < .001); greater than 73% of participants were responders, achieving ≥1 point reduction at all follow‐ups. Participants with baseline reflective Total Nasal Symptom scores ≥ 7 had greater improvement than those with baseline scores < 7 ( P < .001). Greater than 74% of participants were quality of life responders (≥0.4 points) at all follow‐ups with the mini Rhinoconjunctivitis Quality of Life Questionnaire. More than 73% of participants reported PGIC improvement at all follow‐ups. Clinicians noted improvement in 87.1% of participants at 3‐month follow‐up. No device‐ or treatment‐related serious adverse events were reported. Device‐ and treatment‐related adverse events were transient, nonserious, and typically resolved by over‐the‐counter medication and warm beverages. Conclusion: This registry provides additional long‐term evidence of the safety and efficacy of cryotherapy for the treatment of chronic rhinitis in a diverse population through 24 months.
- Open Access
- 13 June 2024
- Published by MDPI AG in Bioengineering
- Vol. 11 (6) , 611
Removal Forces of a Helical Microwire Structure Electrode
(1) Background: Medical devices, especially neuromodulation devices, are often explanted for a variety of reasons. The removal process imparts significant forces on these devices, which may result in device fracture and tissue trauma. We hypothesized that a device’s form factor interfacing with tissue is a major driver of the force required to remove a device, and we isolated helical and linear electrode structures as a means to study atraumatic removal. (2) Methods: Ductile linear and helical microwire structure electrodes were fabricated from either Gold (Au) or Platinum–Iridium (Pt-Ir, 90-10). Removal forces were captured from synthetic gel models and following chronic implantation in rodent and porcine models. Devices were fully implanted in the animal models, requiring a small incision (<10 mm) and removal via tissue forceps. (3) Results: Helical devices were shown to result in significantly lower maximal removal forces in both synthetic gel and rodent studies compared to their linear counterparts. Chronically (1 yr.), the maximal removal force of helical devices remained under 7.30 N, for which the Platinum–Iridium device’s tensile failure force was 32.90 ± 2.09 N, resulting in a safety factor of 4.50. (4) Conclusions: An open-core helical structure that can freely elongate was shown to result in reduced removal forces both acutely and chronically.
- 13 June 2024
- Published by MDPI AG in Bioengineering
- Vol. 11 (6) , 611
Open AccessRemoval Forces of a Helical Microwire Structure Electrode
(1) Background: Medical devices, especially neuromodulation devices, are often explanted for a variety of reasons. The removal process imparts significant forces on these devices, which may result in device fracture and tissue trauma. We hypothesized that a device’s form factor interfacing with tissue is a major driver of the force required to remove a device, and we isolated helical and linear electrode structures as a means to study atraumatic removal. (2) Methods: Ductile linear and helical microwire structure electrodes were fabricated from either Gold (Au) or Platinum–Iridium (Pt-Ir, 90-10). Removal forces were captured from synthetic gel models and following chronic implantation in rodent and porcine models. Devices were fully implanted in the animal models, requiring a small incision (<10 mm) and removal via tissue forceps. (3) Results: Helical devices were shown to result in significantly lower maximal removal forces in both synthetic gel and rodent studies compared to their linear counterparts. Chronically (1 yr.), the maximal removal force of helical devices remained under 7.30 N, for which the Platinum–Iridium device’s tensile failure force was 32.90 ± 2.09 N, resulting in a safety factor of 4.50. (4) Conclusions: An open-core helical structure that can freely elongate was shown to result in reduced removal forces both acutely and chronically.
- 6 March 2024
- Published by Elsevier in Journal of the Mechanical Behavior of Biomedical Materials
- Vol. 153, 106487
Immature porcine cortical bone mechanical properties and composition change with maturation and displacement rate
- 6 March 2024
- Published by Elsevier in Journal of the Mechanical Behavior of Biomedical Materials
- Vol. 153, 106487
Immature porcine cortical bone mechanical properties and composition change with maturation and displacement rate
- 1 January 2022
- Published by Elsevier in Journal of the Mechanical Behavior of Biomedical Materials
- Vol. 125, 104889
Biomechanics of immature human cortical bone: A systematic review
- 1 January 2022
- Published by Elsevier in Journal of the Mechanical Behavior of Biomedical Materials
- Vol. 125, 104889
Biomechanics of immature human cortical bone: A systematic review
- 18 August 2021
- Published by IOP Publishing in Journal of Micromechanics and Microengineering
- Vol. 31 (9) , 095011-10
Irreversible, self-aligned microfluidic packaging for chronic implant applications
Packaging is an often overlooked component in microfluidic devices for biomedical implant applications. Robust and reliable connectors to interface microscale and macroscale features are especially critical for chronic implant applications. Existing microfluidic packaging methods are incompatible with emerging polymeric materials designed to enhance device integration with the surrounding tissue. A microfluidic connector scheme was developed to promote compatibility with novel materials and implant applications. The connectors and an adhesive wax were printed on a scaffold via additive manufacturing processes. The low-temperature packaging process entailed bonding the connector to a polymer nanocomposite-based intracortical microfluidic probe using an adhesive wax. The robustness of the packaging was assessed by measuring the tensile and shear bond strengths of the connector-adhesive wax-polymer film interface. After soak testing for 4 weeks, the bond strength continued to exceed the force required to infuse fluids through the microfluidic channel. Further, the shear bond strength exceeded typical probe insertion forces by at least ten-fold. These results support the use of the connector and thermal bonding method as a viable option for chronic implant applications.
- 18 August 2021
- Published by IOP Publishing in Journal of Micromechanics and Microengineering
- Vol. 31 (9) , 095011-10
Irreversible, self-aligned microfluidic packaging for chronic implant applications
Packaging is an often overlooked component in microfluidic devices for biomedical implant applications. Robust and reliable connectors to interface microscale and macroscale features are especially critical for chronic implant applications. Existing microfluidic packaging methods are incompatible with emerging polymeric materials designed to enhance device integration with the surrounding tissue. A microfluidic connector scheme was developed to promote compatibility with novel materials and implant applications. The connectors and an adhesive wax were printed on a scaffold via additive manufacturing processes. The low-temperature packaging process entailed bonding the connector to a polymer nanocomposite-based intracortical microfluidic probe using an adhesive wax. The robustness of the packaging was assessed by measuring the tensile and shear bond strengths of the connector-adhesive wax-polymer film interface. After soak testing for 4 weeks, the bond strength continued to exceed the force required to infuse fluids through the microfluidic channel. Further, the shear bond strength exceeded typical probe insertion forces by at least ten-fold. These results support the use of the connector and thermal bonding method as a viable option for chronic implant applications.